1 Homologous and heterologous boosting of the ChAdOx1-S1-S COVID-19 vaccine with 2 the SCB-2019 vaccine candidate: a randomized, observer-blinded, controlled, phase 2 3 study 4 Prof. Dr. Sue Ann Costa Clemens, ^{1,2} Dr. Eveline Pipolo Milan, ³ Dr Eduardo Sprinz, ⁴ Dr José 5 Cerbino Neto, ⁵ Dr. Filippo Pacciarini, ⁶ Dr. Ping Li, ⁶ Dr. Hui-Ling Chen, ⁶ Dr. Igor 6 Smolenov, Prof. Dr. Andrew Pollard, Dr. Ralf Clemens 7 8 9 1. Oxford Vaccine Group, Department of Pediatrics, University of Oxford, and the NIHR Oxford Biomedical Research Centre, Oxford, United Kingdom 10 11 2. Siena University, Siena, Italy 3. Centro de Estudos e Pesquisa em Moléstias Infecciosas Ltda. (CEPCLIN), Natal, Brazil 12 13 4. Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil 14 5. D'Or Institute for Research and Education, Rio de Janeiro, Brazil 15 6. Clover Biopharmaceuticals Inc., Cambridge, MA, USA. 16 7. International Vaccine Institute, Seoul, Republic of Korea

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

Registered on ClinicalTrials.gov, NCT 05087368

ABSTRACT Background: Ongoing outbreaks of COVID-19 are driven by waning immunity following primary immunizations and emergence of new SARS-CoV-2 variants which escape vaccineinduced neutralizing antibodies. It has been suggested that heterologous boosters could enhance and potentially maintain population immunity. **Methods:** We assessed immunogenicity and reactogenicity of booster doses of different formulations of alum-adjuvanted SCB-2019 vaccine (9 µg SCB-2019 with or without CpG-1018 adjuvant, or 30 µg SCB-2019 with CpG-1018) in Brazilian adults primed with ChAdOx1-S vector vaccine. S-protein antibodies and ACE2-binding inhibition were measured by ELISA on Days 1, 15 and 29. Participants self-reported solicited adverse events and reactions. Results: All SCB-2019 formulations increased S-protein ELISA antibodies and ACE2 binding inhibition to a greater extent than ChAdOx1-S. After 30 µg SCB-2019+CpG+alum titers against wild-type S-protein were significantly higher than after ChAdOx1-S on Days 15 and 29, as were titers of neutralizing antibodies against wild-type strain and Beta, Gamma, Delta, and Omicron variants. Boosting with SCB-2019 or ChAdOx1-S was well tolerated with no vaccine-related serious or severe adverse events. Conclusions: Boosting ChAdOx1-S-primed adults with SCB-2019 induced higher levels of antibodies against a wild-type strain and SARS-CoV-2 variants than a homologous ChAdOx1-S booster, highest responses being with the 30 µg SCB-2019+CpG+alum formulation. **KEYWORDS** COVID-19; vaccine; booster; heterologous; homologous, SCB-2019; ChAdOx1-S

Conflict of Interest statement 41 42 FP, PL, IE, H-LC, and IS are all full-time employees of the study sponsor. SACC and RC are 43 scientific advisors to the study sponsor. EPM, ES, JCN and AP declare they have no conflicts 44 to declare. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts 45 of Interest and conflicts that the editor considers relevant to the content of the manuscript 46 have been disclosed. 47 48 **Funding statement** 49 The study was sponsored by Clover Biopharmaceuticals Inc. and was supported by grant 50 from Bill & Melinda Gates Foundation (BMGF), No. INV-030336. 51 52 **Corresponding Author** 53 Dr. Ralf Clemens, 54 International Vaccine Institute, 55 SNU Research Park, 56 1 Gwanak-ro, 57 Gwanak-gu, 58 Seoul, 59 08826 Korea 60 E-mail: clemens.ralf@outlook.com 61

INTRODUCTION

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

The COVID-19 pandemic has been ongoing for two years, during which time large proportions of high-income country populations have achieved vaccine-induced immunity following national immunization campaigns [1]. However, new variants of the wild-type severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from Wuhan have continued to emerge each displaying new mutations of the Spike protein (S-protein) [2]. As the Sprotein is the main antigenic target of most of the authorized vaccines, the accumulating mutations have resulted in these new variants becoming successively less susceptible to the neutralizing immunity induced by the first immunization campaigns [3–7]. This has resulted in new waves of pandemic COVID-19 outbreaks, most notably associated with the Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529) variants [8]. The efficacy of authorized vaccines against infection has been seen to decrease with each new variant, both due to waning immunity following immunization and the changes in the antigenic target, while protection against severe disease is largely preserved. This has led to the implementation of further immunization campaigns with booster doses of vaccines to broaden the immune response. Early indications are that heterologous boosters are mostly more effective than homologous boosters [9–11]. Most data on such immunity has been obtained with the mRNA vaccines which were the first to be authorized for use in immunization campaigns and have been widely used in high-income countries. However, many low- and middle-income countries are still in the phase of implementing full primary immunization of their populations, with widespread use of viral vector (e.g., ChAdOx1-S1; AstraZeneca, United Kingdom) or inactivated (e.g., CoronaVac; Sinovac Biotech, China) vaccines. Clover Biopharmaceuticals has developed a recombinant SARS-CoV-2 S-protein vaccine (S-Trimer), SCB-2019, that has been stabilized in the native pre-fusion trimeric conformation using the company's proprietary Trimer-Tag[©] technology and adjuvanted with

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

the toll-like receptor 9 (TLR 9) agonist CpG-1018 and alum. The SPECTRA phase 2/3 efficacy trial demonstrated that two 30 µg doses of SCB-2019 had 67.2% (95.72% CI: 54.3– 76.8) efficacy against any COVID-19, and specific efficacies (with 95% CI) of 78.7% (57.3– 90.4), 91.8% (44.9–99.8) and 58.6% (13.3–81.5) against Delta, Gamma and Mu variants, respectively [12]. The present study was conducted to investigate use of SCB-2019 in heterologous booster regimens compared with homologous boosters in individuals who have received a two-dose primary vaccination series of the adenovirus-vector vaccine, ChAdOx1-S, which was authorized in Brazil. We assessed safety and immunogenicity of different formulations of SCB-2019; low dose (9 µg) SCB-2019 and alum, with and without the CpG-1018 adjuvant to investigate possible dose-sparing, and the standard 30 µg dose formulated with CpG-1018 and alum used in the SPECTRA efficacy trial. These were given as a heterologous booster in persons primed with two doses of ChAdOx1-S and responses compared with a dose of ChAdOx1-S given as a homologous booster. **METHODS** This phase 2 randomized, controlled, observer-blinded, multi-center study is ongoing at three sites in Brazil: Hospital de Clínicas de Porto Alegre, Hospital Gloria D'or, Rio de Janeiro and Centro de Estudos e Pesquisa em Moléstias Infecciosas (CEPCLIN), Natal. The study protocol was approved by each hospital's Ethical Review committee and conducted according to the Declaration of Helsinki and Council for International Organizations of Medical Sciences International ethical guidelines and ICH GCP guidelines. The protocol was registered on ClinicalTrials.gov, registration number NCT 05087368. Participants supplied written informed consent at enrolment. The objective reported here was to select the optimal SCB-2019 formulation to use in the heterologous boosting of individuals primed with two doses of ChAdOx1-S1-S vaccine. Selection was to be based on the safety and immunogenicity, and potential impact on supply of the chosen formulation, i.e. dose-sparing.

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

Participants Eligible participants were male or female adults, ≥ 18 years of age who had previously received two doses of ChAdOx1-S1-S vaccine 6 months (± 4 weeks) before enrolment and were willing and able to comply with study requirements, including all scheduled visits, vaccinations, laboratory tests, and other study procedures. Inclusion criteria included being healthy or having a pre-existing but stable medical condition at the screening examination, the main exclusion criterion being any previous laboratory-confirmed SARS-CoV-2 infection. Vaccine The investigational SCB-2019 vaccine was supplied in a 1.0·mL pre-filled syringe containing 720 µg SCB-2019. Adjuvants were CpG-1018 (Dynavax Technologies) presented in a 2·0 ml vial containing 12 mg/mL of a 22-mer phosphorothioate oligodeoxynucleotide in Tris buffered saline (24 mg per vial), and aluminium hydroxide (Alhydrogel®, Croda Health Care) supplied in vials of 10 mg/mL. The final vaccine formulations per dose contained either 30 µg SCB-2019 with 1.5 mg CpG-1018 and 0.75 mg alum in a 0.5 mL volume, as used in the reported efficacy trial [12], 9 µg SCB-2019 with 0.225 mg alum in a 0.15 mL dose, or 9 µg SCB-2019 with 0.45 mg CpG-1018 and 0.225 mg alum in a 0.15 mL volume. The comparator vaccine (ChAdOx1-S1-S) was Fiorruz COVID-19 vaccine (Rio de Janeiro, Brazil) containing a Chimpanzee Adenovirus (ChadOx1) encoding the SARS-CoV-2 Spike glycoprotein, with not less than 2.5×10^8 infectious units (Inf.U) in each 0.5 ml dose. These vaccine formulations were prepared on the day of use by trained unblinded vaccine administrators who administered them by intramuscular injection in the upper deltoid of the non-dominant arm. For accurate administration of the 0.15 mL volume 1 mL tuberculin syringes (Precisionglide, Becton Dickenson) were used. These vaccine administrators played

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

no further part in the study and all other study staff and the investigators and participants were masked to which vaccine had been given. **Procedures** At enrolment participants were randomly allocated 1:1:1:1 using a block size of 8 to four equal groups to receive a third dose of ChAdOx1-S1 or a dose of one of the three formulations of SCB-2019. At their first study visit on Day 1, after providing their baseline blood sample, participants received their assigned vaccination and were monitored for 30 minutes for any immediate reactions. Using diary cards they then recorded for 7 days the occurrence of solicited local reactions (pain, erythema and swelling at the injection site) and systemic adverse events (fatigue, headache, myalgia, arthralgia, loss of appetite, nausea, chills, fever [axillary temperature ≥ 38°C]) daily, together with any unsolicited adverse events, serious adverse events (SAE) or medically attended adverse events (MAAE) occurring up to the third study visit on Day 29. At this study visit the investigator assessed any reported AE as mild (no interference with daily activities), moderate (interferes with daily activities) or severe (prevents daily activity) and the relationship to the study procedures. *Immunogenicity* Serum samples obtained on Day 1 (before vaccination) and at the second (Day 15) and third (Day 29) visits were used to assess immune responses. The primary endpoint was the response assessed by ELISA as IgG antibodies against SCB-2019 S-protein on Days 15 [12]. Inhibition of binding of S-protein to the human angiotensin converting enzyme 2 (ACE2) was measured using a competitive ELISA with SCB-2019. Additional exploratory analyses included virus neutralizing activity (VNA) titers measured on Days 1, 15 and 29 in a

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

microneutralization assay (MN_{50}) against the prototype Wuhan strain and the Beta (B.1.351), Delta (B.1.617.2), Gamma (P.1) and Omicron (B.1.1.529) variants of SARS-CoV-2. **Statistics** There was no formal hypothesis tested in this first stage of the study, all results being presented and analyzed descriptively. The sample size was considered adequate for the purposes of down-selection of formulation. The primary immunogenicity endpoint was ELISA antibody titers against SCB-2019 S-protein expressed as geometric mean titers (GMT), geometric mean-fold rise in titers over baseline (GMFR) and seroconversion rates (SCR) on Days 15 and 29 in all participants who received the correct vaccination and had no major protocol deviation reported or suffered a COVID-19 infection prior to blood draw. Seroconversion was defined as a \geq 4-fold increase in post-vaccination titer in those with a baseline titer above the lower limit of quantitation (LLOQ), or a post-vaccination titer ≥ 4 fold the LLOQ in those with no detectable activity at baseline. Comparisons between groups were made by ANCOVA model with vaccine group as a fixed variable, baseline antibody result and site as covariates. Immunogenicity results against the different SARS-CoV-2 variants are also expressed as GMTs, GMFR and SCR for group and variant. GMTs of neutralizing antibodies against prototype strain ELISA GMTs against SCB-2019 S-protein are presented in IU/mL, GMTs of neutralizing antibodies against variants and ACE2 are expressed in reciprocal units. Safety data is presented descriptively as proportions of groups (percentage) reporting any solicited reaction or adverse event or unsolicited adverse events. **RESULTS** Recruitment began on November 26, 2021 and the last volunteer was enrolled on March 7, 2022. During this period there was a major outbreak of Omicron infections. Of 144

184

185

186

187

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

volunteers screened a total of 120 volunteers were enrolled and randomized to the four study groups (**Figure 1**). Only two enrolled participants did not complete through visit 3; one was lost to follow-up from Group 1 after visit 1 and the second was lost to follow-up from Group 2 after visit 2. All of the remaining 118 randomized participants completed through visit 3, except for one from Group 1 who did not provide blood for immunology assessment. Demographics in the four study groups were comparable (**Table 1**). Over the course of the study there were 30 suspected cases of COVID-19 in the study population, 26 of which were confirmed by RT-PCR and 2 by rapid antigen test (RAT). These occurred in all four study groups with onset from 8 to 77 days after vaccination (**Table 1**). Three cases had onset before Day 15, and a further ten before Day 29, the remaining 17 having onset after visit 3. The participants with confirmed COVID-19 infection before the second blood sample were excluded from the relevant immunogenicity analyses. **Immunogenicity** Vaccination in any of the four study groups resulted in increases in titers of binding antibodies against SCB-2019 and inhibition of S-protein binding to ACE2 which were notably higher in Groups 1–3 which received the heterologous SCB-2019 formulation than Group 4 after a homologous ChAdOx1-S booster (**Figure 2**). Following the SCB-2019 boosters these increases were apparently dose dependent; in Groups 1 and 2 which received 9 μg SCB-2019 the respective GMFR from Day 1 were 9 and 11 at Day 15 and 8 and 9 at Day 29, while in Group 3 the GMFR were 18 and 16 at Days 15 and 29 suggesting the 30 µg SCB-2019 dose was more effective in inducing a booster response (Figure 2A). Notably, all three SCB-2019 groups elicited significantly higher GMFR than the four-fold increase elicited by the homologous ChAdOx1-S booster vaccination at Day 15. The response increased further in Group 4 at Day 29, but the significant difference persisted between Groups 3 and 4.

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

A similar profile was observed when measuring ACE2 binding (**Figure 2B**) with higher foldincreases in all groups at Days 15 and 29 than with the S-protein assay, which were still dose dependent in the SCB-2019 groups. This immune response was significantly higher in Groups 2 and 3 than in Group 4, the ChAdOx1-S-boosted group and this significant difference persisted at Day 29 when al four groups displayed higher titers with GMFR ranging from 23 to 34 in the three SCB-2019 groups compared with a GMFR of 12 in the ChAdOx1-S group. When assessed for neutralizing activity against the protype strain and the different SARS-CoV-2 variants at Day 15 these differences between different doses of SCB-2019 and between SCB-2019 and ChAdOx1-S were still evident (Figure 3). All groups displayed neutralizing activity against all five variants at baseline, the highest responses being against the prototype Wuhan virus and the lowest against the most recent variant, Omicron (B.1.1529). Two weeks after vaccination there were marked increases against all five variants in all four groups, with significantly higher increases after heterologous SCB-2019 doses in Groups 2 and 3 than the homologous ChAdOx1-S dose in Group 4. Overall, the biggest increases in SCB-2019 groups were against prototype virus with GMFR ranging from 10 to 15 (Table 2) and Delta variant (GMFR 9 to 17), and lowest against Omicron with GMFR ranging from 4 to 6. The GMFR in Group 4, after a booster ChAdOx1-S vaccination, ranged from 2 to 5 for the different variants. When the GMTs of each group vs Group 4 were compared the responses in Groups 2 and 3 were significantly higher than Group 4 against all variants (Figure 3). Similarly, seroconversion rates for each variant were highest with the 30 μg SCB-2019 formulation, with a notably higher response against Omicron than the homologous ChAdOx1-S booster (**Table 2**). Interestingly, the significant differences between Groups 2 and 4, the low-dose fully adjuvanted SCB-2019 and ChAdOx1-S, did into persist to

233

234

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

Day 29 except for the Gamma variant. This was due in equal parts to waning titers in Group 2 and increasing titers in Group 4. Safety Overall, all four vaccine formulations were well tolerated, with no vaccine-related serious or severe adverse events, no withdrawals due to an AE and no deaths (**Table 3**). The only reported SAE was a leg fracture which was not related to the study procedures. One female participant with a history of hypertension and prior COVID-19 infection reported a mild allergic reaction 13 days after vaccination which resolved but was repeated 5 days later. The investigator considered the first occurrence to be related to the study vaccine, but not the second. There were no clinically meaningful differences in rates of solicited local reactions between the groups. Rates were highest in Group 2 (41%) and Group 3 (47%), after 9 µg and 30 µg SCB-2019 with CpG and alum, respectively. The rate was lower (29%) in Group 1 who received 9 µg SCB-2019 with alum alone. After the homologous ChAdOx1-S vaccination 33% of Group 4 reported a local reaction. Local reactions in all four groups mainly consisted of mild pain at the injection site with a few cases described as moderate but none as severe (**Figure 4**). Solicited systemic AEs were most frequently reported after the ChAdOx1-S in Group 4 (63%), with lower rates (39% to 43%) in the SCB-2019 groups. The most frequent solicited systemic AEs were headache, fatigue and myalgia (Figure 4), which were mainly mild and transient, with no severe cases reported. As with local reactions there were no clinically meaningful differences in systemic AEs between groups. There were no AESIs or severe unsolicited AEs reported over the course of the study. As noted, there were 30 cases of COVID-19 reported, including 13 from Day 1 to Day 29 when immunogenicity was assessed. Of these 25 were considered to be mild and 5 as

moderate in severity; no cases were described as severe or had associated pneumonia or required hospitalization.

DISCUSSION

256

257

258

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

This study is the first investigation of boosting immune responses with Clover's recombinant SARS-CoV-2 S-trimer fusion protein vaccine (SCB-2019) as a heterologous vaccine to the primary vaccine. This study also investigated the use of a lower dose of SCB-2019, with and without the CpG-1018 adjuvant, to allow for dose-sparing. The data show that the best booster response in participants primed with two doses of the adenoviral vector vaccine, ChAdOx1-S, was provided by the standard formulation containing 30 µg SCB-2019 with the toll-like receptor 9 agonist CpG-1018 and alum. This formulation demonstrated 67.2% efficacy against COVID-19 of any severity in the SPECTRA study and 100% efficacy against severe disease [12]. As a heterologous booster it was not associated with any safety concerns and had acceptable reactogenicity, comparable to that observed in the SPECTRA study following primary immunizations [12]. The 30 µg SCB-2019 dose elicited significantly higher immunity against the two key antigenic targets, measured as antibodies against SARS-CoV-2 S-protein and inhibition of the binding of S-protein to the ACE2 receptor, than the homologous ChAdOx1-S vaccine. Further, neutralizing antibody responses against four of the major SARS-CoV-2 variants were significantly higher than with the homologous ChAdOx1-S vaccine. These observations are important as ChAdOx1-S has been shown to be highly protective against severe disease and death since its global roll out. One exception was the level of neutralizing activity against the Omicron variant; although significantly lower 15 days after homologous boosting than with heterologous with SCB-2019+CpG+alum formulations, titers against Omicron were comparable at Day 29. This was

281

282

283

284

285

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

partly due to a continuing increase in these titers in the ChAdOx1-S group while they waned slightly in the SCB-2019 groups. The question of whether this indicates a difference in the kinetics of the response to the homologous booster requires further investigation. It has previously been observed that the immune response to a heterologous second vaccination using mRNA vaccines after a primary dose of ChAdOx1-S is more rapid than the homologous vaccination, but we are unaware of similar observations with a protein or inactivated vaccine [13]. The COVID-19 pandemic has decreased in severity but has endured in numbers of infections with the appearance of new variants which despite appearing to be less sensitive to vaccineinduced immunity, are also leading to less severe forms of disease with fewer hospitalizations and deaths [14]. However, SARS-CoV-2 remains a threat to global health, and the experience of a series of novel variants emerging and rapidly predominating in circulation highlights the potential for future outbreaks. In a situation analogous to influenza, in a population that now has immune experience due to infection or vaccination, future variants may lead to seasonal outbreaks. For that reason, it is essential that high levels of immunity are maintained in global populations to ensure there are no more explosive outbreaks of serious illness such as those the world has recently experienced [15]. Many countries have already achieved high levels of immunity, notably those high-income countries that were able to initiate mass immunization campaigns with the first vaccines to be authorized, mainly the mRNA and vector vaccines targeting the S-protein of the prototype virus [1]. Middle- and low-income countries are now playing catch-up, typically using less expensive and more easily managed inactivated vaccines. However, the steady emergence of a series of novel variants, the majority of which have changes in the main antigenic target, the S-protein, has seen a decline in the extent of protective immunity afforded by the initial vaccines [3–8]. The combination of waning antibodies and lower immunity against the novel

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

variant has caused resurgence of COVID-19 outbreaks around the world, which may be countered by use of booster vaccinations [16]. Unfortunately, boosters only provide a temporary solution as waning immunity and emergence of new escape variants means that the added protection will be short-lived. Evidence so far suggests that in most cases boosting with a heterologous vaccine is more effective than homologous boosters [17–19] which this report appears to confirm with the heterologous SCB-2019 booster eliciting higher immunity than a dose of the heterologous ChAdOx1-S vaccine. In view of the global need for more COVID-19 vaccines we also assessed the effect of a reduced dose of SCB-2019 to allow dose-sparing as well as omitting the CpG-1018 adjuvant, which may also be dose-limiting. Our results suggest that both formulations of SCB-2019 with CpG and alum containing 9 µg or 30 µg doses, provide an important boost in immunity with no evidence of increased reactogenicity. This is a small study with several limitations as a consequence, but the trends are confirmation of other observations. Several studies have shown that heterologous booster vaccination can heighten and broaden the immune response compared with homologous booster doses [17–19]. We restricted this study to one priming vaccine, ChAdOx1-S, but results need to be confirmed with other vaccines, particularly mRNA and inactivated vaccines. We only assessed the immune responses out to four weeks after the booster vaccination, and persistence of any improved immune responses following the heterologous and homologous boosters will have to be assessed. Finally, we did not assess the efficacy of the booster immunization; although there were several cases of COVID-19 reported in this small study population it was not designed to include an efficacy assessment which would also require a placebo group. Notably, none of these cases were severe and there were no hospitalizations due to COVID-19.

In conclusion, the formulation of 30 μg SCB-2019 adjuvanted with CpG-1018 and alum is safe and well tolerated and as a heterologous booster vaccine in those previously primed with ChAdOx1-S and is immunologically more effective than that same vaccine given as a homologous booster.

ACKNOWLEDGEMENTS

The authors wish to thank all participants and our co-investigators Drs. Tannyth Gomes dos Santos, Karla Cristina Marques Afonso Ferreira de Souza, and Deyvison Soares da Costa at CEPCLIN, Natal; Drs. Thaina Garbino, Larisse Longo, and Caroline Portela at Hospital de Clínicas de Porto Alegre, Porto Alegre; and Drs. Bruno Pereira Stuchi, Luciana Gomes Pedro Brandão, and Marcellus Dias da Costa at Hospital Glória D'or, Rio de Janeiro for their invaluable contribution to this study. We are grateful to all the personnel at Vismederi SRL (Siena, Italy) for their expertise in performing the immunogenicity assays, to the staff at Smerud Medical Research (Oslo, Norway) for data management, and to Intrials (São Paulo, Brazil) for their conduct of the study. The ChAdOx1-S vaccine used in the study was generously provided by the Ministry of Health (Brasília, Brazil). The authors are grateful to Keith Veitch (keithveitch communications, Amsterdam, the Netherlands) for assistance with preparation and editorial management of the manuscript.

REFERENCES

347

- 348 1. Our World in Data. Coronavirus (COVID-19) vaccinations. Apr 24, 2021.
- https://ourworldindata.org/covid-vaccinations Accessed on April 24, 2022.
- 2. Candido KL, Eich CR, de Fariña LO, et al. Spike protein of SARS-CoV-2 variants: a
- brief review and practical implications. Braz J Microbiol 2022 Apr 9;1–25.
- 352 3. Murano K, Guo Y, Siomi H. The emergence of SARS-CoV-2 variants threatens to
- decrease the efficacy of neutralizing antibodies and vaccines. Biochem Soc Trans 2021;
- 354 49:2879-90.
- 355 4. Madhi SA, Baillie V, Cutland CL, et al. Efficacy of the ChAdOx1 nCoV-19 Covid-19
- 356 vaccine against the B.1.351 variant. N Engl J Med 2021; 384:1885–98.
- 5. V. Shinde S, Bhikha S, Hoosain Z, et al. Efficacy of NVX-CoV2373 Covid-19 vaccine
- against the B.1.351 variant. N Engl J Med 2021; 384:1899–1909.
- Noor R, Shareen S, Billah M. COVID-19 vaccines: their effectiveness against the
- severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its emerging
- variants. Bull Natl Res Cent 2022; 46:96.
- 362 7. Keegan LT, Truelove S, Lessler J. Analysis of vaccine effectiveness against COVID-19
- and the emergence of Delta and other Variants of Concern in Utah. JAMA Network
- 364 Open 2021; 4:e2140906.
- 365 8. Alcantara LCJ, Nogueira E, Shuab G, et al. SARS-CoV-2 epidemic in Brazil: how
- variants displacement have driven distinct epidemic waves. Virus Res 2022; 198785.
- Online ahead of print DOI: 10.1016/j.virusres.2022.198785.
- 9. Pozzetto B, Legros V, Djebali S, et al. Immunogenicity and efficacy of heterologous
- 369 ChAdOx1-BNT162b2 vaccination. Nature 2021; 600:701–6.
- 370 10. Groß R, Zanoni M, Seidel A, et al. Heterologous ChAdOx1 nCoV-19 and BNT162b2
- 371 prime-boost vaccination elicits potent neutralizing antibody responses and T cell
- reactivity against prevalent SARS-CoV-2 variants. EBioMedicine 2022; 75:103761.
- 373 11. Jara A, Undurraga EA, Zubizarreta JR, et al. Effectiveness of homologous and
- heterologous booster doses for an inactivated SARS-CoV-2 vaccine: a large-scale
- prospective cohort study. Lancet Glob Health 2022 Published Online April 23, 2022
- 376 https://doi.org/10.1016/S2214-109X(22)00112-7

377 12. Bravo L, Smolenov I, Han HH, et al. Efficacy of the adjuvanted subunit protein 378 COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, 379 placebo-controlled trial. Lancet 2022; 399:461–72. 380 13. Markewitz R, Juhl D, Paiuli D, et al. Kinetics of the antibody response to boostering 381 with three different vaccines against SARS-CoV-2. Front Immunol 2022; 13:811020. 382 14. Wrenn JO, Pakal SB, Vestal G, et al. COVID-19 severity from Omicron and Delta 383 SARS-CoV-2 variants. Influenza Other Respir Viruses 2022 Online ahead of print Apr 384 13. doi: 10.1111/irv.12982. 385 15. Soraci L, Lattanzio F, Soraci G, et al. COVID-19 vaccines: current and future 386 perspectives. Vaccines (Basel) 2022; 10:608. 387 Menni C, May A, Polidori L, et al. COVID-19 vaccine waning and effectiveness and 16. 388 side-effects of boosters: a prospective community study from the ZOE COVID Study. 389 Lancet Infect Dis 2022 Online ahead of print Apr 8;S1473-3099(22)00146-3. 390 Hayashi JY, Simizo A, Miyamoto JG, et al. Humoral and cellular responses to 391 vaccination with homologous CoronaVac or ChAdOx1 and heterologous third dose 392 with BNT162b2. J Infect Dis 2022; Online ahead of print Feb 27;S0163-393 4453(22)00115-3. doi: 10.1016/j.jinf.2022.02.026. 394 18. Cohen G, Jungsomsri P, Sangwongwanich J, et al. Immunogenicity and reactogenicity 395 after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 396 (AZD1222) vaccines. Hum Vaccin Immunother 2022 Online ahead of print Mar 24;1-397 7. doi: 10.1080/21645515.2022.2052525. 398 19. Parker EPK, Desai S, Marti M, et al. Emerging evidence on heterologous COVID-19

vaccine schedules—To mix or not to mix? Lancet Infect Dis 2022; 22:P438–40.

399

400

Table 1. Demographics of the participants in the Full Analysis Set (FAS).

	Group 1	Group 2	Group 3	Group 4	
Characteristics	9 μg SCB-2019	9 µg SCB-2019	30 µg SCB-2019	ChAdOx1-S	
Cital acteristics	+ alum	+ CpG + alum	+ CpG + alum	CHAUCX1-S	
	N = 30	N = 29	N = 32	N = 29	
Sex, n (%)					
Male	15 (50)	12 (41)	12 (38)	13 (45)	
Female	15 (50)	17 (59)	20 (63)	16 (55)	
Mean age ± SD, yr	43.4 ± 14.4	40.0 ± 13.6	39.8 ± 12.1	36.8 ± 12.7	
(Range)	(20, 66)	(21, 63)	(22, 63)	(21, 64)	
Race, n (%)					
American Indian/Alaskan native	0 (0)	0 (0)	0 (0)	1 (3)	
Black or African American	1 (3)	4 (14)	2 (6)	4 (14)	
White	25 (83)	22 (76)	25 (78)	21 (72)	
Other	2 (7)	3 (10)	4 (13)	2 (7)	
Unknown/not reported	2 (7)	0 (0)	1 (3)	1 (3)	
Ethnic group, n (%)					
Hispanic or Latino	21 (70)	26 (90)	20 (63)	19 (66)	
Not Hispanic or Latino	2 (7)	1 (3)	9 (28)	4 (14)	
Unknown/not reported	7 (23)	2 (7)	3 (9)	6 (21)	
Mean body mass index ± SD, kg/m ²	28.5 (4.9)	28.9 (6.4)	27.5 (5.6)	27.8 (6.5)	
(Range)	(19.8, 37.9)	(17.3, 42.3)	(18.3, 46.3)	(20.0, 44.5)	
Risk of severe COVID-19 ^a , n (%)					
Low	18 (60)	18 (62)	24 (75)	21 (72)	
High	12 (40)	11 (38)	8 (25)	8 (28)	
COVID-19 infections during the study, n (%)	8 (27)	7 (24)	9 (28)	6 (21)	
Time from vaccination, Mean ± SD, days	32.4 ± 12.0	44.3 ± 14.6	24.0 ± 8.2	43.2 ± 23.2	
(Range)	(8, 47)	(32, 67)	(13, 37)	(8, 47)	

a. Risk due to presence of known co-morbidities

Table 2: Geometric mean-fold rises (GMFR) at Days 15 and Day 29 from Day 0, and seroconversion rates (SCR) on Days 15 and 29 for antibodies against the prototype SARS-CoV-2 and four variants measured by microneutralization test (MNT₅₀).

Day	Booster vaccine	Group 1 9 μg SCIB-2019 + alum	Group 2 9 μg SCIB-2019 + CpG + alum	Group 3 30 μg SCIB-2019 + CpG + alum	Group 4 ChAdOx1-S		
PROTOTYPE SARS-CoV-2							
	n	24	25	25	25		
15	GMFR (95% CI)	10 (6–17)	17 (10–30)	15 (9–27)	4 (3–7)		
	SCR (95% CI)	79% (58–93)	84% (64–96)	84% (64–96)	48% (28–69)		
	n	22	24	19	23		
29	GMFR (95% CI)	5 (3–7)	6 (4–11)	13 (7–23)	3 (2–6)		
	SCR (95% CI)	64% (41–83)	71% (49–87)	84% (60–97)	39% (20–62)		
		В	ETA variant				
	n	24	25	25	25		
15	GMFR (95% CI)	7 (5–12)	10 (6–18)	11 (7–20)	5 (3–7)		
	SCR (95% CI)	75% (53–90)	76% (55–91)	80% (59–93)	52% (31–72)		
	n	22	24	19	23		
29	GMFR (95% CI)	6 (4–9)	10 (6–17)	12 (7–20)	6 (3–12)		
	SCR (95% CI)	68% (45–86)	83% (63–95)	90% (67–99)	61% (39–80)		
GAMMA variant							
	n	24	25	25	25		
15	GMFR (95% CI)	11 (7–18)	14 (8–25)	15 (8–28)	5 (3–9)		
	SCR (95% CI)	79% (58–93)	84% (64–96)	80% (59–93)	56% (35–76)		
	n	22	24	19	23		
29	GMFR (95% CI)	6 (4–9)	8 (5–13)	13 (7–25)	4 (2–7)		
	SCR (95% CI)	68% (45–86)	75% (53–90)	79% (54–94)	44% (23–66)		
	DELTA variant						
	n	24	25	25	25		
15	GMFR (95% CI)	9 (5–14)	11 (6–19)	17 (10–27)	5 (3–8)		
	SCR (95% CI)	75% (53–90)	76% (55–91)	88% (69–98)	56% (35–76)		
	n	22	24	19	23		
29	GMFR (95% CI)	6 (4–11)	7 (4–13)	16 (10–27)	5 (2–9)		
	SCR (95% CI)	68% (45–86)	75% (53–90)	90% (67–99)	48% (27–69)		
OMICRON variant							
	n	24	25	25	25		
15	GMFR (95% CI)	4 (2–6)	4 (3–7)	6 (4–10)	2 (1-4)		
	SCR (95% CI)	50% (29–71)	64% (43–82)	68% (47–85)	20% (6.8–41)		
	n	22	24	19	23		
29	GMFR (95% CI)	4 (2–6)	4 (2–6)	5 (3–8)	5 (2–9)		
	SCR (95% CI)	55% (32–76)	58% (37–78)	58% (34–80)	52% (31–73)		

Seroconversion defined as a four-fold increase in titer over baseline at Day 1 or from LLoQ if Day 1 titer was < LLoQ.

GMFR = Geometric mean fold rise from Day 1 at Day 15 or Day 29

Table 3. Reactogenicity in the 29 days after the booster doses of vaccines as indicated in the Safe	ety population.
--	-----------------

	Group 1	Group 2	Group 3	Group 4
Vaccine	9 µg SCB-2019 + alum	9 μg SCB-2019 + CpG + alum	30 μg SCB-2019 + CpG + alum	ChAdOx1-S
	N = 30	N = 29	N = 32	N = 29
Any solicited local AE	8/28 (29%)	11/27 (41%)	14/30 (47%)	9/27 (33%)
Mild	7/28 (25%)	11/27 (41%)	13/30 (43%)	8/27 (30%)
Moderate	1/28 (4%)	0/27 (0%)	1/30 (3%)	1/27 (4%)
Any solicited systemic AE	11/28 (39%)	14/27 (52%)	13/30 (43%)	17/27 (63%)
Mild	9/28 (32%)	10/27 (37%)	7/30 (23%)	13/27 (48%)
Moderate	2/28 (7%)	4/27 (15%)	6/30 (20%)	4/27 (15%)
Any unsolicited AE				
Any SOC	10 (33%)	19 (66%)	16 (50%)	11 (38%)
Grade 3 related	0	0	0	0
Grade 3 not related	0	1	0	0
Serious adverse events (SAE)				
Any	0	1 (3%)*	0	0
Related	0	0	0	0
Medically attended AE (MAAE)	5 (17%)	7 (24%)	9 (28%)	6 (21%)
AE of special interest (AESI), AE leading to early withdrawal, or death	0	0	0	0

^{*} One participant suffered a leg fracture which was considered to be unrelated to the study.

Figure legends

- **Figure 1.** Study flow chart showing the disposition of the participants to each of the four groups.
- **Figure 2.** Booster vaccination responses shown as geometric mean titers (95% CI) of ELISA antibodies against SCB-2019 (panel **A**) and ACE2 (panel **B**) at Days 15 and 29 after vaccination. Geometric mean-fold rises (GMFR) from Day 1 (95% CI) are shown with ANCOVA p values of differences between Groups 1-3 (SCB-2019) and Group 4 (ChAdOx1-S): * p <0.05; ** p < 0.01, *** p < 0.001). Numbers in columns are n values per group.
- Figure 3. Booster vaccination responses shown as geometric mean neutralizing titers (with 95% CI) against the indicated SARS-CoV-2 variants 15 days after vaccination. Differences in GMTs of Groups 1-3 vs. Group 4 at Day 15 were tested by ANCOVA; * p < 0.05; ** p < 0.01; *** p < 0.001.
- **Figure 4.** Solicited local reactions and systemic adverse events occurring within 7 days of vaccination by severity reported as percentages of each group.

Figure 1




Figure 2.




Figure 3.




Figure 4.

